CD8A and neoplasm: The number of tumor-infiltrating WT1-specific CD8+ lymphocytes was demonstrated to be two-fold higher in mice treated with DSP-7888 Emulsion plus anti-PD-1 vs DSP-7888 Emulsion plus an isotype control antibody (1.76 vs 0.80%) (Fig. 4A).